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ABSTRACT
Background: The methods used to estimate health-state utility values
(HSUV) for multiple health conditions can produce very different values.
Economic results generated using baselines of perfect health are not com-
parable with those generated using baselines adjusted to reﬂect the HSUVs
associated with the health condition. Despite this, there is no guidance on
the preferred techniques and little research describing the effect on cost per
quality adjusted life-year (QALY) results when using the different methods.
Methods: Using a cardiovascular disease (CVD) model and cost per
QALY thresholds, we assess the consequence of using different baseline
health-state utility proﬁles (perfect health, no history of CVD, general
population) in conjunction with models (minimum, additive, multiplica-
tive) frequently used to approximate scores for health states with multiple
health conditions. HSUVs are calculated using the EQ-5D UK preference-
based algorithm.
Results: Assuming a baseline of perfect health ignores the natural
decline in quality of life associated with age, overestimating the beneﬁts
of treatment. The results generated using baselines from the general
population are comparable to those obtained using baselines from indi-
viduals with no history of CVD. The minimum model biases results in
favor of younger-aged cohorts. The additive and multiplicative models
give similar results.
Conclusion: Although further research in additional health conditions is
required to support our ﬁndings, our results highlight the need for analysts
to conform to an agreed reference case. We demonstrate that in CVD, if
data are not available from individuals without the health condition,
HSUVs from the general population provide a reasonable approximation.
Keywords: decision models, health economics methods, health surveys,
health-state utility, methodology.
Introduction
A number of agencies, including the National Institute for Health
and Clinical Excellence (NICE), require economic evidence to be
presented in the form of cost-effectiveness analyses whereby
health beneﬁts are quantiﬁed by quality adjusted life-years
(QALYs) [1]. QALYs are calculated by summing the time spent in
a health state weighted by the health-state utility value (HSUV)
associated with the health state, thus incorporating both length
of survival and HSUVs into a single metric. Classiﬁcation systems
can produce a wide range of values for the same health state and
the economic results generated using different systems are not
always comparable [1]. Consequently, for submissions in the UK,
the Institute advocate a preference for EQ-5D data with HSUVs
obtained using UK population weights when available [1].
However, this is not sufﬁcient to ensure consistency across
appraisals because there is no guidance on appropriate baseline
HSUVs that should be used to quantify the underlying health
condition for patients entering the model [1]. If a baseline utility
of perfect health (i.e., EQ-5D equals 1) is used to represent the
absence of a health condition, the incremental QALYs gained by
an intervention are inﬂated [2] and the results obtained using a
baseline of perfect health are not comparable with those obtained
when the baseline is adjusted for not having a particular health
condition [3]. There is currently no consensus on baseline HSUVs
used in economic evaluations.
In addition, there is currently no directive on the method that
should be used to combine HSUVs for multiple health condi-
tions. Analysts are increasingly exploring the beneﬁts of inter-
ventions in individuals with several comorbid conditions. For
example, HMG-CoA reductase inhibitors (statins) reduce both
cardiovascular (CV) risk and rheumatoid arthritis (RA) disease
activity; and an economic model exploring the beneﬁts of statins
in this population would include health states for patients with a
history of both RA and cardiovascular disease (CVD) [4].
Because of strict exclusion criteria preventing patients with
comorbidities entering clinical trials, it is unlikely that HSUVs
will be available from patients with both health conditions.
When HSUVs for the multiple health states are not available,
approximate scores are estimated by combining data collected
from patients with the individual health conditions. Three
methods are frequently used: 1) additive; 2) multiplicative; and 3)
minimum models. The additive and multiplicative models
assume a constant absolute or proportional effect, respectively,
while the minimum model applies a disutility that can vary
depending on the baseline utility modeled. Research exploring
the appropriateness of the techniques used to combine utility
values is inconclusive. The additive and multiplicative models
have been shown to produce similar results for individuals with
both diabetes and thyroiditis [5]; the multiplicative model pro-
duced accurate utilities for several comorbid conditions [6]; and
the minimum model was advocated as the preferred methodol-
ogy in two other studies [7,8].
Although literature describing minimum requirements for
probabilistic analyses is growing [9], research exploring the basic
principles involved in using HSUVs in economic models, and the
implications for results generated from the models when using
different techniques is scarce. The limited research undertaken in
this area has explored the appropriateness of different baseline
utilities and approximate HSUVs for multiple health conditions
in isolation; and there is currently no consensus on the preferred
methodologies when the two adjustments are undertaken
together.
We describe the results of a pilot study in which we explore
the effect of using different baseline utility values and different
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techniques to estimate approximate HSUVs for multiple health
conditions in combination. We use an existing economic model
and data from the Health Survey for England to investigate the
potential effect on policy decision-making using cost per QALY
thresholds. The primary objective of the study is to instigate
additional research in this area to provide a foundation for better
practice in economic evaluations used to inform health care
decision-makers in the UK and elsewhere.
Methods
The following section provides a brief description of the eco-
nomic model and a synopsis of the data used.
Cardiovascular Model
An existing peer-reviewed Markov model [10] was modiﬁed
slightly so that the health states (Fig. 1) matched the deﬁnitions
of three CV conditions available from the Health Survey for
England which are angina (A), heart attack (HA) and stroke (Str)
[10,11]. The model compares two alternative treatments and an
annual cycle is used for transitions between health states. Indi-
viduals enter the model in the event-free (EF) health state and can
move to a primary health state: angina (A), nonfatal heart attack
(HA), or nonfatal stroke (Str), or remain in the EF health state.
Individuals in the primary and post-event health states can move
to a subsequent health state: subsequent angina (SA), subsequent
nonfatal HA (SHA), subsequent nonfatal stroke (SStr); or remain
in the primary or post-event health state. In each cycle all indi-
viduals are at risk of death through other causes (DoC), or fatal
CVD (fCVD). Health-state costs are taken from a recent HTA
evaluation of lipid treatments in the UK [10].
Health Survey for England
The Health Survey for England (HSE) is conducted annually
using random samples of the population living in private house-
holds in England. The 2003 and 2006 surveys included questions
about history of CVD and a random sample of participants (aged
16 to 98 years) were asked to complete the EQ-5D questionnaire
(N = 26,679) [11,12]. Preference-based HSUVs were estimated
using the weights obtained using time trade off valuations from
the UK general public [13].
We assumed that the data from individuals who reported a
history of just one CV condition are representative of the HSUVs
of individuals who have a ﬁrst ever primary CV event; and that
data from individuals who reported a history of more than one
CV condition are representative of the HSUVs of individuals who
have a subsequent event (Table 1). For example, the mean HSUV
during the ﬁrst 12 months after experiencing a primary (second-
ary) heart attack is 0.721 (0.431) and the corresponding mean
HSUV for time periods after this is 0.742 (0.685).
The relationship between HSUVs, age, sex, and history
of CVD was explored using ordinary least square regres-
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Figure 1 Health states in cardiovascular model.
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sions. Model 1 (EQ-5D = 0.9508566 + 0.0212126*male -
0.0002587*age - 0.0000332*age2, Fig. 2) was obtained using
the full dataset (n = 26,679) and can be used to estimate the
mean HSUVs for individuals in the general population. Model
2 (EQ-5D = 0.9454933 + 0.0256466*male - 0.0002213*age -
0.0000294*age
2, Fig. 2) was obtained from individuals who
reported no history of angina, heart attack or stroke (n = 25,080)
and can be used to estimate the HSUVs for individuals with no
history of CVD [14].
Analyses
The following section describes a worked example demonstrat-
ing the difference in incremental QALYs gained from avoiding a
single event when using different baseline HSUV proﬁles, fol-
lowed by results generated from the economic model demon-
strating the potential effect on a policy decision using a cost per
QALY threshold when using the different baseline HSUV pro-
ﬁles. We then provide a worked example using the three alterna-
tive models to estimate approximate scores for multiple health
conditions, looking at the difference in incremental QALYs asso-
ciated with avoiding a single event, followed by results generated
from the economic model when combining the different baseline
proﬁles and the techniques used to combine the utility data.
Baseline HSUV Proﬁles
In a CV model, individuals who are at high risk of a CV event
and have no prior history of CVD typically enter the model in an
Table 1 EQ-5D scores sub\grouped by health condition and time since event
Health condition
Health
state N
Age EQ-5D
SEMean Mean
Utility values used to populate health states in the economic model
Event-free EF 25,080 47.0 0.872 0.001
Angina <12 months, history of just angina A 271 68.8 0.615 0.019
No event <12 months, history of just angina pA 246 68.0 0.775 0.015
Angina <12 months, history of angina + other CV condition SA 245 67.9 0.541 0.022
No event <12 months, history of angina + other CV condition pSA 184 69.4 0.715 0.022
Heart attack <12 months, history of just heart attack HA 31 65.4 0.721 0.045
No event <12 months, history of just heart attack pHA 206 65.1 0.742 0.020
Heart attack <12 months, history of heart attack + other CV condition SHA 36 66.7 0.431 0.066
No event <12 months, history of heart attack + other CV condition pSHA 184 69.2 0.685 0.024
Stroke <12 months, history of just stroke Str 76 67.9 0.626 0.038
No event <12 months, history of just stroke pStr 291 66.8 0.668 0.018
Stroke <12 months, history of stroke + other CV condition SStr 18 73.5 0.479 0.087
No event <12 months, history of stroke + other CV condition pSStr 77 70.4 0.641 0.037
Data used to compare methods for estimating proxy scores for multiple
health conditions
Angina (t = ever), history of just angina 517 68.4 0.691 0.013
Heart attack (t = ever), history of just heart attack 237 66.6 0.739 0.018
Stroke (t = ever), history of just stroke 367 67.0 0.660 0.016
Angina and heart attack (t = ever) 323 68.2 0.624 0.019
Angina and stroke (t = ever) 63 70.3 0.596 0.043
Heart attack and stroke (t = ever) 32 69.7 0.538 0.065
Angina <12 months and heart attack <12 months 23 63.1 0.400 0.073
Angina <12 months and heart attack >12 months 154 68.4 0.585 0.030
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Figure 2 Baseline utility for the event-free health state: Relationship between HSUVs, age, sex, and history of CVD.
Issues Involved in Applying HSUV in Models 511
“event-free” health state. The HSUV proﬁle associated with this
health state is then used as the baseline to estimate the health
beneﬁts accrued through avoiding CV events. Ideally, the health
proﬁle for the EF health state would be derived from long term
registry data and would represent the HSUVs for individuals who
are at high risk of a primary CV event but who have no existing
history of CVD. In the absence of these data, analysts assume the
baseline HSUV proﬁle is either 1) equal to perfect health (i.e.,
EQ-5D = 1 irrespective of age or sex), 2) equal to the proﬁle of
HSUVs from the general population adjusted for age and sex
(i.e., all individuals irrespective of history of CVD), or 3) equal to
the proﬁle of HSUVs from individuals with no history of CVD.
To simplify the methodology, we present examples for males only
in the following section.
In the following example (Box 1), we illustrate the difference
in QALYs accrued from avoiding a single event using the three
alternative baseline HSUV proﬁles for the EF health state. The
HSUV proﬁle when assuming a baseline of perfect health (UPHEF)
is constant at EQ-5D = 1. The HSUV proﬁle when assuming a
baseline from the individuals with no history of CVD (UNCVEF) is
calculated using Model 2 and the HSUV proﬁle when assuming
a baseline from the general population (UGPEF) is calculated using
Model 1 (Fig. 2). The mean EQ-5D score for individuals who
reported experiencing angina within the previous 12 months (UA)
is 0.6148 and the mean age for this subgroup is 68.8 years
(Table 1). We assume the event occurs at the age of 50 years and
examine the cumulative and incremental QALYs accrued over a
50-year time horizon. For the examples using the age-adjusted
baseline proﬁles, the data for the individual health conditions are
combined multiplicatively (see Box 2 for more details on this
technique).
The cumulative QALYs for the EF health state are calculated
by summing the life-years weighted by the HSUV proﬁle
across the 50 year period (Cumulative QALYPHEF = 50*1, Cumu-
lative QALY Model 2NCVEF
50 age 99
= =
≤ ≤
∑ 39 27. , Cumulative
QALY Model 1GPEF
50 age 99
= =
≤ ≤
∑ 38 08. ). The cumulative QALYs
for angina are calculated by summing the life-years weighted by
the baseline proﬁle multiplied by the multiplier associated with
angina (Cumulative QALYPHA = 50*1*0.6148 = 30.74, Cumula-
tive QALY Model 2 0.753NCVA
50 age 99
= ∗ =
≤ ≤
∑ 29 56. , Cumulative
QALY Model 1GPA
50 age 99
= ∗ =
≤ ≤
∑ 0 771 29 37. . . The incremental
QALYs associated with avoiding angina is calculated as the dif-
ference between the total cumulative QALYs for the EF health
state minus the total cumulative QALYs for angina (Cumulative
QALYiEF - Cumulative QALYA). The technique used to obtain
the multipliers is described in the next worked example.
Comparing results when using different baseline HSUV proﬁles
for the EF health state. For a male, the cumulative QALYs
(Box 1) associated with remaining in the EF health state range
from 38.1 when using a baseline HSUV proﬁle from the general
population to 50 when using a baseline HSUV proﬁle of perfect
health; and the cumulative QALYs associated with angina
range from 29.4 when using a baseline HSUV proﬁle from the
general population to 30.7 when using a baseline HSUV proﬁle
of perfect health. The incremental QALY gain associated with
avoiding angina range from 8.71 when using a baseline HSUV
proﬁle from the general population to 19.26 when using a
baseline HSUV proﬁle of perfect health. The incremental
QALYs obtained using the baseline HSUV proﬁle from the
general population are comparable to those obtained when
using the baseline HSUV proﬁle from individuals with no
history of CVD (8.71 vs. 9.71).
Looking at the QALY gain associated with avoiding a single
heart attack or a stroke (Table 2), the values obtained when
assuming a baseline HSUV proﬁle of perfect health are substan-
tially higher than those obtained using the age adjusted data.
Box 1
Comparing the incremental QALY gain from a single event when using different baseline HSUV proﬁles
Let UPHEF = 1
UNCVEF = 0.9454933 + 0.0256466 * male - 0.0002213 * age - 0.0000294 * age2
UGPEF = 0.9508566 + 0.0212126 * male - 0.0002587 * age - 0.0000332 * age2
UA = 0.6148 (mean age = 68.8 years)
Where Uij = HSUV, and i = baseline: PH = perfect health
NCV = no history of CVD (regression Model 2)
GP = general population (regression Model 1)
j = health state: EF = event-free, A = angina
multiplier for angina for UNCV: male = 0.753 (= 0.6148/0.8167)
multiplier# for angina for UGP: male = 0.771 (= 0.6148/0.7973)
(# see example 2 for method used to obtain multipliers)
Results when assuming a baseline HSUV proﬁle of full health:
Cumulative QALYPHEF = 50
Cumulative QALYPHA = 30.74
Incremental QALYPH = QALYPHEF - QALYPHA = 19.26
Results when using a baseline HSUV proﬁle from individuals with no history of CVD:
Cumulative QALYNCVEF = 39.27
Cumulative QALYNCVA = 29.56
Incremental QALYNCV = QALYNCVEF - QALYNCVA = 9.71
Results when assuming a baseline HSUV proﬁle from the general population:
Cumulative QALYGPEF = 38.08
Cumulative QALYGPA = 29.37
Incremental QALYGP = QALYGPEF - QALYGPA = 8.71
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Again, the QALY gain obtained using the baseline HSUV proﬁle
from the general population are comparable to those obtained
using the baseline HSUV proﬁle from individuals with no history
of CVD (heart attack: 4.30 vs. 5.18; stroke: 8.33 vs. 9.30).
Cost per QALY Results Using Different Baseline HSUV
Proﬁles for the EF Health State
The three alternative baseline proﬁles were applied in the CVD
model and used to assess the lifetime beneﬁts associated with
avoiding primary events for cohorts of differing ages (Table 3).
The results from the worked example show the beneﬁts asso-
ciated with avoiding a single event are considerably larger when
using a baseline of perfect health compared to adjusting the
baseline. When examining the effect on the results generated
from the model, the cost per QALY obtained using a baseline
of perfect health (Fig. 3) is substantially lower than the corre-
sponding results obtained using the age-adjusted proﬁles,
particularly for the older aged cohorts. If a threshold of
£20,000 per QALY is applied (Fig. 3), using a baseline of
perfect health could potentially induce a different policy deci-
sion than the one based on results generated when using a base-
line HSUV proﬁle that is adjusted for not having the health
condition.
Estimating Approximate HSUV for Multiple
Health Conditions
In the following example (Box 2), we use data from individuals
who have a history of angina and no other CV condition (UA)
and data from individuals who have a history of a heart attack
and no other CV condition (UHA) to estimate an HSUV for the
multiple health state “angina and heart attack” (UA,HA). The
additive, multiplicative and minimum models are used to esti-
mate the HSUV proﬁles for the multiple health condition using
the disutility (dij), multiplier (jij) or minimum value (min), respec-
tively. These are then used in conjunction with the two age-
adjusted baseline HSUV proﬁles (no history of CVD and general
population) but not the baseline of perfect health. We compare
the QALYs obtained from avoiding a single event when using the
Box 2
Estimating an approximate HSUV for the multiple health state both angina and heart attack
Let j = health state and: AHA = both angina and heart attack, A = angina, HA = heart attack, A,HA = approximate angina plus
heart attack
dij = disutility; jij =multiplier; min = minimum
UAHA @ mean age 68.2 = 0.6243, UGP @ age 68.2 = 0.8000, UNCV @ age 68.2 = 0.8193
UA @ mean age 68.4 = 0.6910, UGP @ age 68.4 = 0.7990, UNCV @ age 68.4 = 0.8185
UHA @ mean age 66.6 = 0.7391, UGP @ age 66.6 = 0.8076, UNCV @ age 66.6 = 0.8260
Using a baseline HSUV proﬁle from individuals with no history of CVD,
Additive: dNCVAHA = UNCV - UAHA = 0.8193 - 0.6243 = 0.1950
dNCVA,HA = dNCVA + dNCVHA = (UNCV - UA) + (UNCV - UHA)
= (0.8185 - 0.6910) + (0.8260 - 0.7391) = 0.2143
Multiplicative: jNCVAHA = UAHA/UNCV = 0.6243/0.8193 = 0.7622
jNCVA, HA = jNCVA * jNCVHA = (UA/UNCV)*(UHA/UNCV)
= (0.6910/0.8185)*(0.7391/0.8260) = 0.7555
Minimum: UNCVAHA = min(UNCV,UAHA) = min(UNCV,0.6243)
UNCVA,HA = min(UNCV,UA,UHA) = min(UNCV,0.6910,0.7391)
Assuming the event occurs at the age of 50 years,
Using the data from individuals with a history of both angina and heart attack:
Additive, incremental QALYsNCV = QALYNCVEF - QALYNCVAHA = 39.27 - 29.52 = 9.75
Multiplicative, incremental QALYsNCV = QALYNCVEF - QALYNCVAHA = 39.27 - 29.92 = 9.35
Minimum, incremental QALYsNCV = QALYNCVEF - QALYNCVAHA = 39.27 - 31.22 = 8.05
Using the approximate scores from individuals with a history of either angina or heart attack:
Additive, incremental QALYsNCV = QALYNCVEF - QALYNCVA,HA = 39.27 - 28.55 = 10.72
Multiplicative, incremental QALYsNCV = QALYNCVEF - QALYNCVA,HA = 39.27 - 29.67 = 9.60
Minimum, incremental QALYsNCV = QALYNCVEF - QALYNCVA,HA = 39.27 - 34.46 = 4.81
When using a baseline HSUV proﬁle from the general population, the approximate HSUVs are calculated using the same method
as above replacing the values from individuals with no history of CVD with the corresponding values from the general population.
The results are provided in Table 4. N.B. any anomalies in the results are caused by rounding in the decimal places in the calculations
shown above.
Table 2 Cumulative and incremental QALYs associated with a single
event using different baseline utility data
Multiplicative Model
Cumulative
QALY
Incremental
QALY
Baseline: perfect health
Event-free 50.00
Angina 30.74 19.26
Heart Attack 36.07 13.94
Stroke 31.31 18.69
Baseline: from general population
Event-free 38.08
Angina 29.37 8.71
Heart attack 33.78 4.30
Stroke 29.75 8.33
Baseline: from individuals with
no history of CVD
Event-free 39.27
Angina 29.56 9.71
Heart attack 34.09 5.18
Stroke 29.97 9.30
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HSUV (UAHA) from individuals who have a history of both angina
and a heart attack with those obtained when using the estimated
HSUV (UA,HA).
A. Using the HSUV obtained from individuals with a history of
both angina and heart attack. The mean HSUV for individuals
with a history of both angina and heart attack (UAHA) is 0.6243,
and the mean age for this subgroup is 68.2 years. When using the
baseline HSUV proﬁle from the general population, the HSUV
for a male at the age of 68.2 years (UGP) is 0.8000 (from Model
1). For the additive model, the disutility (dGPAHA) is the absolute
difference between the baseline utility at the age of 68.2 years
and the HSUV associated with the health condition angina
and heart attack (i.e., dGPAHA = UGP-UAHA = 0.8000 - 0.6243 =
0.1757). When summing the QALYs accumulated for the health
condition, as the additive model assigns a constant effect irre-
spective of age, a constant value of 0.1757 is deducted from
the age-adjusted baseline HSUV each year and the resulting
values are summed to give the total cumulative QALYs
(QALY Model 1GPAHA AHAGP
50 age 99
= − =
≤ ≤
∑ δ 29 30. ). The incremen-
tal QALYs are then calculated by deducting the total cumulative
QALYs associated with the condition angina and heart attack
(QALYGPAHA = 29.30) from the baseline total cumulative QALYs
for the EF health state (QALYGPEF = 38.08).
For the multiplicative model, the multiplier (jGPAHA) is the
value that will give the HSUV associated with the health condi-
tion angina and heart attack (UAHA) when multiplying the base-
line utility at the age of 68.2 years (i.e., jGPAHA = UAHA/
UGP = 0.6243/0.8000 = 0.7804). When summing the QALYs
accumulated for the health condition, the multiplicative model
assigns a constant proportional effect which is dependent on the
age-adjusted baseline HSUV. The total cumulative QALYs are
calculated by summing the QALYs obtained when multiplying
the age-adjusted baseline HSUV with the corresponding multi-
plier (QALY Model 1GPAHA AHAGP
50 age 99
= ∗( ) =
≤ ≤
∑ ϕ 29 72. ). The
Table 3 Results generated from CVD model using the three alternative baseline proﬁles (combining utility scores multiplicatively)
Baseline utility
Treatment A
QALYs
Treatment B
QALYs
Incremental
QALYs
Cost per
QALY
Age 50 years
Costs £(,000) £4,216 £5,610 £1,394
Perfect health 16,795 16,895 100 £13,887
General population 14,129 14,178 49 £28,324
No history of CVD 14,363 14,417 54 £25,914
Age 60 years
Costs £(,000) £3,660 £4,773 £1,113
QALYs Perfect health 13,582 13,648 67 £16,711
General population 10,919 10,952 33 £33,957
No history of CVD 11,197 11,229 32 £34,777
Age 70 years
Costs £(,000) £2,609 £3,424 £815
QALYs Perfect health 9,966 10,002 36 £22,849
General population 7,643 7,656 13 £62,195
No history of CVD 7,866 7,880 14 £56,487
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Figure 3 Comparing the results generated from the CVD model using the three alternative baseline proﬁles.
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incremental QALYs are then calculated by deducting the total
cumulative QALYs associated with the condition angina and
heart attack (QALYGPAHA = 29.72) from the baseline total cumu-
lative QALYs for the EF health state (QALYGPEF = 38.08). For the
minimum model, the minimum HSUV for the multiple condition
angina and heart attack, and the age-adjusted baseline is used.
Consequently, the detriment associated with the health condition
angina plus heart attack is not constant. The total cumulative
QALYs is simply the sum of the minimum value each year
(QALY min Model 1, UGPAHA AHA
50 age 99
= ( ) =
≤ ≤
∑ 31 21. ). The incre-
mental QALYs are then calculated by deducting the total cumu-
lative QALYs for the health-state angina plus heart attack
(QALYGPAHA = 31.21) from the baseline total cumulative QALYs
for the EF health state (QALYGPEF = 38.08).
B. Using the HSUV obtained from individuals with a history of
either angina (with no other CV condition) or heart attack (with
no other CV condition). The mean HSUV for individuals with a
history of just angina (UA) is 0.6910 and the mean HSUV for
individuals with a history of just heart attack (UHA) is 0.7391.
The mean ages for these subgroups are 68.4 and 66.6 years,
respectively. When using the baseline HSUV proﬁle from the
general population, the corresponding HSUVs for a male at the
age of 68.4 and 66.6 years are 0.7990 and 0.8076 (from Model
1). For the additive model, the total disutility (dGPA,HA) is
estimated to be the sum of the absolute difference between
the baseline utility at the age of 68.4 and the HSUV asso-
ciated with the health condition angina (i.e., dGPA = UGP-
UA = 0.7990 - 0.6910 = 0.1080) plus the absolute difference
between the baseline utility at the age of 68.4 and the HSUV
associated with the health condition heart attack (i.e.,
dGPHA = UGP-UHA = 0.8076 - 0.7391 = 0.0686), giving a total
estimated detriment of 0.1766. When summing the QALYs accu-
mulated for the health condition, a constant value of 0.1766 is
deducted from the age-adjusted baseline HSUV each year and
the resulting values are summed to give the total cumulative
QALYs (QALY Model 1GPA HA AHAGP
50 age 99
, .= −( ) =
≤ ≤
∑ δ 29 25). The
incremental QALYs are then calculated by deducting the total
cumulative QALYs (QALYGPA,HA = 29.25) from the baseline total
cumulative QALYs for the EF health state (QALYGPEF = 38.08).
For the multiplicative model, the estimated multiplier for the
health-state angina and heart attack (jGPA,HA) is calculated by
multiplying the multiplier for angina (jGPA) with the multiplier
for heart attack (jGPA). The single multipliers are calculated using
the method described earlier, that is, the multiplier for angina is
obtained using the HSUV for angina and the baseline HSUV for
individuals at the age of 68.4 years (jGPA = 0.6910/0.7790) and
the multiplier for heart attack is obtained using the HSUV for
heart attack and the baseline HSUV for individuals at the age of
66.6 years (jGPA = 0.7391/0.8076). When multiplied together,
the estimated multiplier for the combined conditions angina and
heart attack (jGPA,HA) is 0.7913. The total cumulative QALYs are
calculated by summing the QALYs obtained when multiplying
the age-adjusted baseline HSUV with the corresponding multi-
plier (QALY Model 1GPA HA A HAGP
50 age 99
, , .= ∗( ) =
≤ ≤
∑ ϕ 30 13). The
incremental QALYs are then calculated by deducting the total
cumulative QALYs associated with the condition angina and
heart attack (QALYGPA,HA = 30.13) from the baseline total cumu-
lative QALYs for the EF health state (QALYGPEF = 38.08).
For the minimum model, the minimum HSUV for the
individual conditions angina and heart attack, and the age-
adjusted baseline is used. The total cumulative QALYs is
simply the sum of the minimum value each year
(QALY min Model 1, U , UGPA HA A HA
50 age 99
, .= ( ) =
≤ ≤
∑ 34 14). The
incremental QALYs are then calculated by deducting the esti-
mated total cumulative QALYs for the health-state angina plus
heart attack (QALYGPA,HA = 34.14) from the baseline total cumu-
lative QALYs for the EF health state (QALYGPEF = 38.08).
Comparing ResultsWhen Estimating Approximate
HSUVs for Multiple Health Conditions
When using age-adjusted baseline utilities from the general popu-
lation to represent the HSUV for the EF health state, and the
HSUV for individuals with a history of both angina and heart
attack, the incremental QALYs obtained using the additive and
the multiplicative models are 8.79 and 8.36, respectively, com-
pared with 6.87 when using the minimum model. The corre-
sponding incremental QALYs obtained when estimating HSUVs
for the combined health state are 8.83, 7.95, and 3.94 for the
additive, multiplicative, and minimum models, respectively. If it
is assumed that the values obtained using the data from individu-
als with both health conditions are correct, then the additive and
multiplicative models produce much smaller errors in the incre-
mental values than the minimum model.
Using age-adjusted baseline utilities from individuals with no
history of CVD to represent the HSUV proﬁle for the EF health
state (calculations provided in Box 2), the additive and the mul-
tiplicative models again produce similar results with incremental
QALYs of 10.72 and 9.60, respectively, compared with 9.75 and
9.35 when using the data from individuals with a history of both
conditions. The incremental QALY gain when using the
minimum model is much smaller at 4.81 and 8.05 when using the
HSUV from the individual health conditions and the HSUV from
individuals with both health conditions, respectively. Results for
additional examples (n  20) are provided in Table 4.
Cost per QALY Results GeneratedWhen Combining the
Alternative Baseline HSUV Proﬁles with the Three
Different Models Available to Combine HSUVs
The three alternative techniques used to combine utility
scores are applied in the CVD model and used to assess the
lifetime beneﬁts associated with avoiding primary events
for cohorts of differing ages using a baseline from indivi-
duals with no history of CVD and a baseline from indivi-
duals from the general population (Table 5). The results from
the second worked example showed the beneﬁts associated
with avoiding a single event are considerably smaller when using
the minimum model to combine the utility values. This has
a larger effect on the results for older aged cohorts (Table 5)
where the ratio of costs and QALYs are more sensitive to
small differences in the number of incremental QALYs gained.
Figure 4 shows the cost per QALY results generated from
the model using the different techniques to combine the utility
data. There is very little difference in the results for the additive
and multiplicative models, with the baseline HSUVs having
a larger effect than the technique used to combine the utility
data.
Discussion
We have demonstrated that the difference in QALY beneﬁts
accrued from avoiding a single CV event when using a baseline of
perfect health are not comparable with those accrued when using
a baseline that is adjusted for not having CVD. We have also
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demonstrated that in CVD, results generated using age-adjusted
data from the general population are comparable to those
obtained using a baseline from individuals with no history of
CVD. Applying the different approaches in an economic model,
we also show that assuming an HSUV proﬁle of perfect health as
the baseline could potentially inﬂuence a policy decision based on
a cost per QALY threshold.
The HSE data show that both age and sex are independent
predictors of HSUVs and these ﬁndings are observed in numer-
ous other datasets [13,16]. Given that the mean EQ-5D score is
never equal to full health irrespective of age or sex, using a
baseline of perfect health overestimates the beneﬁts associated
with avoiding an event and biases the results in favor of the older
age cohorts because it ignores the natural decline in mean HSUVs
because of age and comorbidities. Data obtained from individu-
als without the health condition under consideration is the ideal
baseline proﬁle and should be used where possible. However, if
these data are not available, we show that in CVD, the results
generated using age-adjusted baseline data from the general
population are comparable with the results generated using age-
adjusted baseline data from individuals with no history of CVD.
It should be noted that for the ﬁrst example where we explore
the effect on the ICER of using different baseline proﬁles we
combine the data for the age-adjusted analyses using the multi-
plicative model. We could have combined the data additively or
used the minimum model but felt that presenting all three sets of
results added an unnecessary complexity to the methods and
detracted from the purpose of the exercise which was twofold.
Table 4 Cumulative and incremental QALY gains from a single event using different techniques to estimate proxy scores for multiple health states
Cumulative QALY Incremental QALY
Error in Incremental QALYObserved* Proxy† Baseline – observed Baseline – proxy
GP NCVD GP NCVD GP NCVD GP NCVD GP NCVD
Baseline
Event-free 38.1 39.3
Angina plus Heart Attack: EQ-5D just angina = 0.691; EQ-5D just heart attack = 0.739; EQ-5D angina plus heart attack = 0.624
Additive 29.3 29.5 29.2 28.5 8.8 9.8 8.8 10.7 0.0 1.0
Multiplicative 29.7 29.9 30.1 29.7 8.4 9.4 7.9 9.6 -0.4 0.2
Minimum 31.2 31.2 34.1 34.5 6.9 8.1 3.9 4.8 -2.9 -3.3
Angina plus Stroke: EQ-5D just angina = 0.691; EQ-5D just stroke = 0.660, EQ-5D angina plus stroke = 0.596
Additive 28.4 28.5 25.4 24.7 9.7 10.7 12.7 14.6 3.0 3.9
Multiplicative 28.7 28.9 27.0 26.5 9.4 10.4 11.1 12.7 1.8 2.3
Minimum 29.8 29.8 32.9 33.0 8.3 9.5 5.2 6.3 -3.1 -3.2
Heart Attack plus Stroke: EQ-5D just heart attack = 0.739, EQ-5D just stroke = 0.660; EQ-5D heart attack plus stroke = 0.538
Additive 25.3 25.5 27.4 26.7 12.8 13.8 10.7 12.6 -2.0 -1.2
Multiplicative 25.8 26.0 28.6 28.1 12.2 13.3 9.5 11.1 -2.7 -2.1
Minimum 26.9 26.9 32.9 33.0 11.2 12.4 5.2 6.3 -6.0 -6.1
Angina <12 months, Heart Attack <12 months:
EQ-5D angina <12 months = 0.615; EQ-5D heart attack <12 months = 0.721; EQ-5D angina <12 months plus heart attack <12 months = 0.400
Additive 16.9 17.3 24.4 23.7 21.2 22.0 13.7 15.6 -7.5 -6.4
Multiplicative 18.5 18.7 26.1 25.7 19.6 20.6 12.0 13.6 -7.6 -7.0
Minimum 20.0 20.0 30.8 30.8 18.1 19.3 7.3 8.5 -10.8 -10.8
Angina <12 months, Heart Attack >12 months:
EQ-5D angina <12 months = 0.615; EQ-5D heart attack >12 months = 0.742; EQ-5D angina <12 months plus heart attack >12 months = 0.585
Additive 27.4 27.6 25.4 24.7 10.7 11.7 12.7 14.6 2.0 2.9
Multiplicative 27.9 28.1 26.8 26.4 10.2 11.2 11.3 12.9 1.1 1.7
Minimum 29.3 29.3 30.8 30.8 8.8 10.0 7.3 8.5 -1.5 -1.5
*Using utility data from individuals with a history of both conditions; †Using data from individuals with a history of a single condition to estimate the HSUV for the multiple health condition.
GP, general population; NCVD, No history of CVD.
Table 5 Results generated from the CVD model when combining different baseline utility scores and different methods to combine utility data
General population No history of CVD
Additive Multiplicative Minimum Additive Multiplicative Minimum
Age 55 years
Treatment A, total QALY 12,530 12,535 12,565 12,790 12,794 12,827
Treatment B, total QALY 12,573 12,577 12,605 12,837 12,841 12,870
Incremental QALY 43 43 40 47 47 43
Cost per QALY £29,109 £29,394 £31,742 £26,664 £26,927 £29,088
Age 65 years
Treatment A, total QALY 9,257 9,262 9,298 9,510 9,515 9,553
Treatment B, total QALY 9,282 9,286 9,318 9,537 9,542 9,576
Incremental QALY 25 24 20 27 27 23
Cost per QALY £38,680 £39,553 £47,253 £35,235 £36,021 £42,767
Age 75 years
Treatment A, total QALY 6,038 6,042 6,067 6,251 6,256 6,284
Treatment B, total QALY 6,049 6,053 6,075 6,264 6,268 6,293
Incremental QALY 11 11 8 13 12 9
Cost per QALY £58,521 £61,078 £82,287 £52,676 £54,892 £74,144
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First, to reiterate ﬁndings previously described by Flanagan, i.e.,
that using a baseline of perfect health over estimates the beneﬁts
of treatment, and second, to take the research one step further by
exploring the potential effect on policy decisions using results
generated from an economic model.
We demonstrated that when combined with the age-adjusted
utilities, the method used to estimate approximate scores for
multiple health conditions can produce a large variation in the
incremental QALY gain from avoiding a single event. When
applying the techniques in the economic model we demonstrate
that the method used to estimate the approximate scores could
affect a policy decision based on a cost per QALY threshold. In
particular, using the minimum model in combination with an
age-adjusted baseline produces results that are not comparable to
those generated using the additive or multiplicative models.
The existing literature describing the effect on results when
combining HSUVs using different methods is sparse and incon-
clusive. Both Dale et al. and Fu et al. suggest the minimum value
should be used to approximate the HSUV for a multiple health
condition [7,8]. By taking the minimum mean utility score of the
individual health conditions that contribute to a multiple health
condition, the minimum model assumes that comorbidity has no
additional detrimental effect on the HSUV of individuals with an
existing health condition. This is counterintuitive and data from
the HSE show that, in CVD, there is a statistically signiﬁcant
difference in the mean EQ-5D score for individuals with one
condition compared with those with more than one CV condi-
tion (mean EQ-5D for individuals with a history of just
angina = 0.691, mean EQ-5D for individuals with a history of
angina and stroke = 0.596, P < 0.01). In addition, when applying
the minimum model in an economic model in conjunction with
an age-adjusted baseline, the method fails. The HSUVs for indi-
viduals who experience a primary heart attack is 0.7213. In the
primary prevention analyses where all individuals commence in
the EF health state the age-adjusted EQ-5D score for males with
no history of CVD at the age of 89 years is 0.718. Consequently,
when using the minimum model there is no beneﬁt in avoiding a
non fatal heart attack in males over the age of 89 years. Similarly,
the post primary angina health state has a mean EQ-5D score of
0.775; thus, there are no beneﬁts for males aged over 78 as the
corresponding baseline age-adjusted EQ-5D score for individuals
with no history of CVD is 0.7748. Because the minimum model
does not apply a constant detriment, the technique introduces a
bias against older aged cohorts and the results from our thresh-
old analyses demonstrate this can be quite substantial. We there-
fore recommend that the minimum model is not used to combine
utility scores.
The authors of a recent publication propose a linear function
to estimate HSUVs for combined health states which combines
the three commonly used models. The weights for the function
were obtained from a sample (n = 207) of men at the time of
prostate biopsy. Although the authors found their weighted
linear function outperformed the three individual models in
terms of bias in the mean residuals and correlations of the residu-
als with the predicted HSUVs, these results are based on a base-
line of perfect health [15].
Our results show that the multiplicative and additive models
produce similar results both for the individual events and when
applying the techniques in the economic model. Flanagan and
colleagues found the multiplicative model was reasonably accu-
rate in estimating both double and triple comorbidities after
“purifying” the mean HUI3 scores to adjust for not having 26
chronic conditions [6]. Bond et al. concluded that the additive
and multiplicative models produced very similar results, when
using a baseline of perfect health [5]. However, the additive
model applies a constant absolute detriment across all ages while
the multiplicative model applies a constant proportional detri-
ment. In real terms, this means that the additive model provides
a greater absolute reduction in HSUVs than the multiplicative
model and the magnitude of the detriment is constant across all
ages irrespective of the number of comorbidities. The ﬁndings
from Dale et al. and Fu et al., who both advocate the minimum
model for combining HSUVs outside of an economic model,
support the hypothesis that the detriment associated with several
comorbidities may not equal the sum of the individual
detriments.
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Figure 4 Comparing results generated from the CVD model when combining different baseline utility scores and different methods to combine utility data.
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Saarni reported that the mean number of comorbid chronic
conditions increases from 1.1 for the age group 30–44 years to 4.0
for those aged 75 years and older [16]. It is possible that as the
number of comorbidities increase, the detriment associated with
an additional condition is smaller than that observed in an indi-
vidual with just two comorbidities. If this hypothesis is correct,
then the detriment associated with additional conditions would
not be constant across all ages because of the increasing prevalence
of comorbidities. In addition, health conditions can impact on the
same health dimensions and it is reasonable to assume that an
individual with two ormore similar conditionswill not necessarily
have a reduction in HSUV that is equal to the sum of the
reductions observed for each of the individual health conditions.
Although we found the additive and multiplicative models
produced similar cost per QALY results, this ﬁnding may not
generalize with other health conditions. In health conditions with
comparatively small gains in QALYs, for example, when the
intervention does not have an effect on mortality rates, the eco-
nomic results are likely to be more sensitive to changes in the
techniques used to combine HSUVs. Although additional
research is required to support our hypothesis and ﬁndings, in the
interim period, to facilitate comparison across results generated
from models with multiple health states, we advocate the use of
the multiplicative model for the reasons discussed above regard-
ing the potential limitations associated with the additive model.
The health care literature and policy decision-makers such as
NICE place a great deal of emphasis on both the methods used to
obtain weights used in preference-based instruments and the
particular preference-based instrument used to collect the HSUVs
which are used to populate health states within economic models
[1]. Evidence shows that the choice of instrument used to repre-
sent the HSUVs of a particular health condition can inﬂuence the
results generated [17]. However, there is a great deal more to
populating an economic model than the choice of instrument
used to obtain the HSUVs and a consistent approach would
improve comparability of results. We have used EQ-5D data in
this article and additional research using alternative data such as
the SF-6D is warranted.
Conclusion
Our results reinforce earlier recommendations and, until guide-
lines are in place, we would recommend that data from the
general population are used as approximate baseline utility mea-
sures for individuals without the health condition under consid-
eration if the actual data are not available. Although our ﬁndings
demonstrate the additive and multiplicative models give similar
results in CVD, additional research in other health conditions
and datasets are required.
The underlying principle behind using the same preference-
based instrument for all economic evaluations is to enable com-
parison across different interventions and health conditions. If
this is to be realized, some consensus is needed on the most
appropriate methods to populate the economic models. The
methods used should be clearly described to inform policy
decision-makers who are comparing results generated from dif-
ferent evaluations.
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